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A B S T R A C T  
Objective: Determination of diabetes mellitus among Hepatitis C Virus associated with chronic liver disease patients. 
Patients and Methods: This cross sectional study was conducted in the central laboratory, department of Chemical 
Pathology, Allama Iqbal Medical College, Lahore, from 1stMay 2016 to 31stJanuary 2017. A total of 201 known cases of 
Chronic liver disease were included from medical wards of the Jinnah Hospital, Lahore. About 02 ml blood sample was 
collected from each individual for estimation of Fasting Blood Glucose and HbA1c. Patients were labeled as diabetic or 
non–diabetic according to the criteria for the diagnosis of diabetes mellitus described by American Diabetes Association 
2017. 
Results: Out of these 201 cases, 51% (n=103) were males and 49% (n=98) were females. Mean age of all participants 
was 55.2 + 10.6 years.  Mean fasting blood glucose level was 201.9+111.0 mg/dl. Total 24.9% patients were found non-
diabetic and remaining 75.1% were declared as diabetics. 
Conclusion: High rate of diabetes mellitus was observed among hepatitis C virus associated chronic liver disease 
patients. 
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I n t r o d u c t i o n  
 
Diabetes mellitus is one of the commonest diseases 
around the globe, and it is expected that by the year 2030 
there will be 366 million people affected globally.1 In the 
year 2000, global mortality due to diabetes was 2.9 
million.2  In Pakistan, It is estimated that 6.3 million 
persons have an age adjusted 7.9% prevalence  of 
persons with diabetes (PWD) among adults, 20 years or 
older.3  Pakistan, in 2030 will have an estimated 11.4 
million persons with PWD and prevalence of 8.9% in the 
absence of major medications.4 
There are many causes for Chronic Liver Disease (CLD), 
from which Hepatitis C Virus is most common. HCV was 
documented in 1989 as the primary agent of non-A, non-B 
hepatitis, which at the time accounted for almost 90 
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percent of all transfusion transmitted hepatitis cases in the 
United States.5 Hepatitis C infection is one of the most 
alarming health problems globally, with an incidence of 
200 million (3.3%) of the world’s population.6 Currently, 
about 4 million individuals in the United States are 
infected with HCV and 2.7 million of these people are 
acareers.7 Nearly 30,000 new cases of HCV have been 
diagnosed annually, and more than two thirds appear to 
be related to parenteral route.8  It is estimated that >10 
million peoples are infected with HCV in Pakistan.9 
HCV primarily affects the liver and ultimately causes 
cirrhosis,end-stage liver disease and hepatocellular 
carcinoma.10 HCV-associated CLD is responsible for 
8,000-10,000 mortalities per year and for 25 percent of all 
liver transplantations in the United States.8,11Association 
of DM and liver cirrhosis was first described by Bohan et 
al 12 and designated as hepatogenous diabetes in a study 
conducted by Megyesi et al13 in which 57% of cirrhotic 
patients were found to have insulin resistance. Near about 
80% of CLD patients may be glucose intolerant and 
between 10–20% may be clinically diabetic.14 The liver is 
chiefly responsible for glucose homeostasis and store or 
release of glucose according to metabolic needs. In 
diabetes or insulin resistant states, impaired hepatic 
glucose release contributes considerably to the 
pathophysiology of those conditions. HCV infection is a 
known risk factor for hepatocellular carcinoma (HCC) and 
rising risk of HCC by 2–4 folds even after adjusting for 
other predisposing factors.14 Acute or chronic liver disease 
can augment insulin resistance and effects of insulin on 
hepatocyte are disturbed.15 In presence of hepatic 
disease, the metabolic homeostasis of glucose is 
deranged as a result of insulin resistance, glucose 
intolerance, and diabetes. Insulin resistance develops not 
only in muscle but also in adipose tissue which combined 
with hyperinsulinemia may seem as important 
pathophysiologic basis of diabetes in chronic liver 
disease.16 Glucose absorbed from the intestinal tract is 
transported from portal vein to liver where most of the 
glucose is retained by the liver so that most of the rise in 
peripheral glucose concentration is a reflection of only a 
minor component of postprandial absorbed glucose. It is 
suggested that liver plays a more significant role than 
peripheral tissues in maintaining systemic blood glucose 
level following a meal.14 
DM in patients of CLD may be subclinical hepatogenous 
diabetes is clinically different from type 2 DM since it is 
less frequently associated with microangiopathy and 
patients more often undergo complications of cirrhosis 
and increase the death rate is because of cirrhosis.16 
There are several international studies, that have reported 
association of diabetes with CLD, but very few such 
studies have been published from our region. The 
rationale behind this study was to ascertain the frequency 
of DM in patients of CLD. 
P a t i e n t s  a n d  M e t h o d s  
This cross sectional study was conducted in Department 
of Chemical Pathology, Allama Iqbal Medical College, 
Lahore, from 1st May 2015 to 31st January 2016. Study 
was approved by ethical review board of the Institute. 
Total 201 patients of HCV associated chronic liver 
diseases of either gender were inducted from medical 
wards of the Jinnah Hospital, Lahore. Diagnosis of CLD 
was made by clinician of the ward on the basis of 
laboratory investigations and ultrasonography.18 Patients 
with acute stage of liver disease, renal failure, known for 
Diabetes, HBV or any other virus career and those who 
refused to become the part of the study were excluded 
from the study. All participants were requested for 
overnight (10–12 hours) fast. Next morning 01 ml blood 
sample in sodium fluoride tube was collected from each 
individual for estimation of FBG. Similarly, 01 ml blood 
was taken in EDTA tube for HbA1c analysis. All 
specimens were transported to the lab under 
standardized conditions. Centrifugation was done at 2500 
rpm for 5-7 minutes. Blood glucose was estimated by 
endpoint enzymatic (Glucose Oxidase – PAP) method, 
using diagnostic reagents on semi-automated chemistry 
analyzer (MicroLab-300) manufactured by Merck. HbA1c 
was analyzed by Beck-man coulter Access 2 automatic 
special chemistry analyzer by using immunoassay 
technique. Based on the findings of FBG and HbA1c, 
patients were labeled as diabetic or non–diabetic 
according to the criteria for the diagnosis of DM as 
described by American Diabetes Association 2017. SPSS 
21.0 was used for statistical analysis. Frequency and 
percentages were calculated 
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Among 201 cases, 51% participants (n=103) were males 
and 49% (n=98) were females. Mean age of all patients 
was 55.2 + 10.6 years.  Mean FBG was 201.9+111.0 
mg/L. Total 24.9% individuals were found non-diabetic 
and remaining 75.1% were declared as diabetics (Table 
1). Thus diabetic population was 75 % (151/201) of the 
whole study population. Among 75 % of diabetic 
population, 49% (74/151) were female and 51% (77/151) 
were male. 
 
Table 1: Fasting Glucose and Glycated Hemoglobin 
in CLD patients 
Groups Frequency Percentage 
Non-Diabetic (Glucose < 
100 mg/dl), HbA1c (<6.5%) 
50 24.9 
Diabetic (Glucose ≥ 126 
mg/dl), HbA1c (≥6.5%) 
151 75.1 
Total 201 100 
D i s c u s s i o n  
Hyperglycemia is seen in patients of CLD, after ingestion 
of oral glucose, resulting in hyperglycemia in central 
circulation and leading to impairment of glucose uptake by 
peripheral tissues due to insulin resistance.8 In our study, 
250 cases of CLD have been evaluated for the 
prevalence of DM. We found that 75% of our study 
population was diabetic. Multiple researchers have 
reported the prevalence of DM (12.9 – 23.2%) from 
different regions of the globe.19-21 In Pakistan, the 
previously reported prevalence of DM is 18.7 – 34.8%.22-24 
This rate is low as compared to our study. The basic 
reason for this higher prevalence is still unknown but few 
researchers have reported that persons of old age 40 
years or above with hepatitis C infections are more likely 
to have diabetes.25 Our findings are in agreement with 
this. Another reason for this highest prevalence may be 
due to the population difference as previous researches 
has been done in different areas of Pakistan but our study 
population was patients admitted in Jinnah Hospital, 
Lahore which one of the major referral/teaching hospital 
of the province. Among 75 % (151/201) of diabetic 
population, 49% (74/151) were female and 51% (77/151) 
were male. The gender difference was not a significant 
factor in our study as both genders were almost equally 
enrolled. However, in a previous study, it was found that 
DM was dominant in males.26 
Many researchers have also reported the association of 
chronic liver disease and impaired glucose tolerance. A 
study conducted in Larkana, Pakistan reported 78% 
prevalence of DM in a population of cirrhosis.27 The exact 
pathophysiology underlying the association of chronic 
hepatitis C with DM is still unknown. A detailed knowledge 
of the underlying cause of HCV associated glucose 
metabolism disturbance is warranted, in order to improve 
clinical management of chronic hepatitis C patients.28,29 
Accumulation of fat in liver cells is also a factor for the 
development of insulin resistance as described by many 
researchers. Steatosis in HCV positive cases is also 
closely related to expression of HCV core protein and 
possibly, it is related to change metabolic profile.30 All 
patients who are suspected for CLD should be screened 
for DM from time to time. If management of high blood 
glucose level is addressed in patients of CLD, this will 
reduce the risk of complications associated with diabetes 
in these patients. This study was a single center cross 
sectional study with small sample size. Multicenter Cohort 
studies should be conducted on a large sample size so 
the exact phenomena for the development of DM in 
chronic liver disease cases may be described. 
C o n c l u s i o n  
The frequency of diabetes mellitus in patients suffering 
from chronic liver disease was high. This can be 
controlled and managed by the early detection of blood 
glucose level in chronic liver disease cases. Early 
detection of DM may avoid micro or macro angiopathic 
complications of DM and life expectancy of such patients 
can be improved. 
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